BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoarthritis Inhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis. Expression levels of the ROR2 ligand WNT5A were higher in human osteoarthritic cartilage than in healthy cartilage. In a mouse fibroblast...
BioCentury | Oct 7, 2020
Politics, Policy & Law

FDA to stop reviewing COVID-19 lab tests, raising concerns in Congress

In a move that raises concerns about the accuracy of tests, as well as liability protections for laboratories, FDA announced Wednesday that it will no longer review emergency use authorization requests for laboratory-developed tests to...
BioCentury | Oct 2, 2020
Distillery Therapeutics

Blocking a lipid hydrolase for liver fibrosis

DISEASE CATEGORY: Hepatic INDICATION: Liver fibrosis; non-alcoholic steatohepatitis (NASH) Inhibiting ASAH1, an enzyme that hydrolyzes ceramide, could treat liver fibrosis. In patients with chronic HCV infection, levels of ASAH1 in hepatic stellate cells were higher in...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Repurposed integrin inhibitor for cardiac wound healing

DISEASE CATEGORY: Cardiovascular INDICATION: Myocardial infarction (MI) Cilengitide, an integrin αvβ3 and integrin αvβ5 inhibitor tool compound, could treat post-myocardial infarction injury driven by COL5 deficiency. In mouse cardiac fibroblasts with COL5A1 knockout, cilengitide reduced the...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Antisense-mediated exon skipping for X-linked Alport syndrome

DISEASE CATEGORY: Renal INDICATION: Renal Exon skipping therapy with an antisense oligonucleotide (ASO) targeting a truncating variant in exon 21 of COL4A5 could treat severe X-linked Alport syndrome. The ASO led to complete exon 21...
BioCentury | Dec 19, 2019

Skin grafts based on CRISPR-edited iPS cells to treat epidermolysis bullosa

DISEASE CATEGORY: Dermatology INDICATION: Blistering disorder Skin grafts based on CRISPR-edited induced pluripotent stem (iPS) cells could treat recessive dystrophic epidermolysis bullosa, a blistering disorder caused by mutations in COL7A1. Generation of the full-thickness grafts...
BioCentury | Dec 17, 2019

Inhibiting tankyrase to treat osteoarthritis and regenerate cartilage

DISEASE CATEGORY: Autoimmune disease INDICATION: Osteoarthritis Combined TNKS and TNKS2 inhibition could treat osteoarthritis, which features progressive cartilage degeneration, and enhance the efficacy of stem cell-based therapies for cartilage regeneration. In osteoarthritis patients, TNKS and...
BioCentury | Oct 28, 2019

Enleofen co-founders identify IL-11 as pulmonary fibrosis target

DISEASE CATEGORY: Pulmonary INDICATION: Pulmonary fibrosis A National Heart Centre Singapore team led by Enleofen Bio Pte. Ltd. co-founders Stuart Cook and Sebastian Schafer showed that inhibiting IL-11 could treat pulmonary fibrosis. Levels of IL-11...
BioCentury | Oct 11, 2019
Company News

Oct. 11 Company Quick Takes: FDA approves Lilly migraine drug; plus Clovis, Evotec-Celmatix, Avacta-ADC and Neumentum-J&J

FDA approves Lilly’s Reyvow for migraine FDA approved Reyvow lasmiditan from Eli Lilly and Co. (NYSE:LLY) to treat acute migraine with or without aura. It is the first agonist of serotonin (5-HT1F) approved for the...
BioCentury | Sep 12, 2019
Distillery Therapeutics

Tumor-targeted serum albumin-chemotherapy conjugates for improved delivery to breast and colorectal cancers

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; colorectal cancer Delivering chemotherapies through conjugation to tumor-targeted albumin could treat breast and colorectal cancers. Albumin is fused with collagen-binding domain of vWF to facilitate attachment to the tumor...
Items per page:
1 - 10 of 175